LYZ and diabetic kidney disease: To validate the expression changes, the tubulointerstitial transcriptome of DKD patients was analyzed using Nephroseq v5, confirming elevated CASP1 and LYZ mRNA levels compared to controls (Figures 4(e) and 4(f)).